Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden

References

• Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 to 1994. N Engl J Med 1999; 341: 566–62
   Web of Science ®Google Scholar
• Nguyen MH, Keeffe EB. Epidemiology and treatment outcomes of patients with chronic hepatitis C and genotypes 4 to 9. Rev Gastroent Dis 2004; 4(Suppl 1)S14–21
   PubMedGoogle Scholar
• Socialstyrelsen, Hälso- och sjukvårdsstatistisk årsbok 2002 [Yearbook of Health and Medical Care 2002]. 2002; Stockholm: Socialstyrelsen.
   Google Scholar
• Wong JB, McQuillan GM, McHutchison JG, Poynard T. Estimating future hepatitis C morbidity, mortality, and costs in the United States. Am J Public Health 2000; 90: 1562–9
   PubMed Web of Science ®Google Scholar
• Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic hepatitis C virus. Lancet 1998; 352: 1426–32
   PubMed Web of Science ®Google Scholar
• Sennfält K, Reichard O, Hultkrantz R, Wong JB, Jonsson D. Cost-effectiveness of interferon alfa-2b with and without ribavirin as therapy for chronic hepatitis C in Sweden. Scan J Gastroenterol 2001; 36: 870–6
   PubMed Web of Science ®Google Scholar
• Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958–65
   PubMed Web of Science ®Google Scholar
• Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virological response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645–52
   PubMed Web of Science ®Google Scholar
• Reichard O, Norkrans G, Fryden A, Braconier JH, Sönnerborg A, Weiland O and, the Swedish Study Group. Randomized, double-blind, placebo-controlled trial of interferon alfa-2b with and without ribavirin for chronic hepatitis C. Lancet 1998;351:83–7.
   PubMed Web of Science ®Google Scholar
• Bennett WG, Inoue Y, Beck R, Wong JB, Pauker SG, Davis GL. Estimates of the cost-effectiveness of a single course of interferon alfa-2b in patients with histologically mild chronic hepatitis C. Ann Intern Med 1997; 127: 855–65
   PubMed Web of Science ®Google Scholar
• Christensen E, Krintel J, Hansen S, Johansen J, Juhl E. Prognosis after the first episode of gastrointestinal bleeding or coma in cirrhosis. Survival and prognostic factors. Scand J Gastroenterol 1989; 24: 999–1006
   PubMed Web of Science ®Google Scholar
• Graffeo M, Buffoli F, Lanzani G, Donato F, Cesari P, Benedini D, et al. Survival after endoscopic sclerotherapy for oesophageal varices in cirrhotics. Am J Gastroenterol 1994; 89: 1815–22
   PubMed Web of Science ®Google Scholar
• Takahashi M, Yamada G, Miyamoto R, Doi T, Endo H, Tsuji T. Natural course of chronic hepatitis C. Am J Gastroenterol 1993; 88: 240–3
   PubMed Web of Science ®Google Scholar
• Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328: 1797–801
   PubMed Web of Science ®Google Scholar
• Gane EJ, Portmann BC, Naoumov NV, Smith HM, Underhill JA, Donaldson PT, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996; 334: 815–20
   PubMed Web of Science ®Google Scholar
• Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–40
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997; 112: 463–72
   PubMed Web of Science ®Google Scholar
• Dore GJ, Freeman AJ, Law M, Kaldor JM. Is severe liver disease a common outcome for people with chronic hepatitis C?. Journal of Gastroenterology and Hepatology 2002; 17: 423–30
   PubMed Web of Science ®Google Scholar
• Dore GJ, Freeman AJ, Law M, Kaldor JM. Natural history models for hepatitis C-related liver disease: different disease progression parameters for different settings. Antiviral Therapy 2003; 8: 365–72
   PubMed Web of Science ®Google Scholar
• Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russel LB. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA 1996; 276: 1253–8
   PubMed Web of Science ®Google Scholar
• Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. German hepatitis C model (GEHMO) group, international hepatitis interventional therapy (IHIT) group. Cost effectiveness of peginterferon alfa-2b plus ribavirin versus interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut 2003; 52: 425–32
   PubMed Web of Science ®Google Scholar
• Wong J, Poynard T, Ling M-H, Albrecht JK, Pauker SG. Cost-effectiveness of 24 or 48 weeks of interferon alfa-2b alone or with ribavirin as initial treatment of chronic hepatitis. Am J Gastroenterol 2000; 95: 1524–30
   PubMed Web of Science ®Google Scholar
• Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Aliment Pharmacol Ther 2003; 17: 687–94
   PubMed Web of Science ®Google Scholar
• Zeuzem S, Hultcrantz R, Bourliere M, Goeser T, Marcellin P, Sanches-Tapias J, et al. Peg-interferon alfa-2b plus ribavirin for treatment of chronic hepatitis C in previously untreated patients infected with HCV genotypes 2 or 3. J Hepatol 2004; 40: 993–9
   PubMed Web of Science ®Google Scholar
• Deuffic-Burban S, Wong JB, Valleron A-J, Costagliola D, Delfraissy J-F, Poynard T. Comparing the public health burden of chronic hepatitis C and HIV infection in France. J Hepatol 2004; 40: 319–26
   PubMed Web of Science ®Google Scholar